BR112023018607A2 - Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior - Google Patents

Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior

Info

Publication number
BR112023018607A2
BR112023018607A2 BR112023018607A BR112023018607A BR112023018607A2 BR 112023018607 A2 BR112023018607 A2 BR 112023018607A2 BR 112023018607 A BR112023018607 A BR 112023018607A BR 112023018607 A BR112023018607 A BR 112023018607A BR 112023018607 A2 BR112023018607 A2 BR 112023018607A2
Authority
BR
Brazil
Prior art keywords
treatment
depressive disorder
major depressive
disubstituted
steroid
Prior art date
Application number
BR112023018607A
Other languages
English (en)
Portuguese (pt)
Inventor
Senoaji Adiwijaya Bambang
Handan Gunduz-Bruce
James Doherty
Martin Jonas Jeffrey
Lisa Dunbar Joi
Alfonso Lasser Robert
Jay Kanes Stephen
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of BR112023018607A2 publication Critical patent/BR112023018607A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112023018607A 2021-03-17 2022-03-17 Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior BR112023018607A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162501P 2021-03-17 2021-03-17
US202163284592P 2021-11-30 2021-11-30
PCT/US2022/020716 WO2022197901A1 (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Publications (1)

Publication Number Publication Date
BR112023018607A2 true BR112023018607A2 (pt) 2023-10-24

Family

ID=81327141

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018607A BR112023018607A2 (pt) 2021-03-17 2022-03-17 Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior

Country Status (11)

Country Link
US (1) US20240245711A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308162A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510436A (cg-RX-API-DMAC7.html)
KR (1) KR20230158033A (cg-RX-API-DMAC7.html)
AU (1) AU2022238365A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018607A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213744A1 (cg-RX-API-DMAC7.html)
IL (1) IL305858A (cg-RX-API-DMAC7.html)
MX (1) MX2023010728A (cg-RX-API-DMAC7.html)
TW (1) TW202300156A (cg-RX-API-DMAC7.html)
WO (1) WO2022197901A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders

Also Published As

Publication number Publication date
TW202300156A (zh) 2023-01-01
MX2023010728A (es) 2024-02-12
JP2024510436A (ja) 2024-03-07
US20240245711A1 (en) 2024-07-25
WO2022197901A1 (en) 2022-09-22
KR20230158033A (ko) 2023-11-17
EP4308162A1 (en) 2024-01-24
CA3213744A1 (en) 2022-09-22
IL305858A (en) 2023-11-01
AU2022238365A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
Klawans et al. Levodopa‐induced dopamine receptor hypersensitivity
BR112021018627A2 (pt) Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
Real et al. Exercise-induced plasticity of AMPA-type glutamate receptor subunits in the rat brain
CO5670356A2 (es) Programa de dosificaicon para un nuevo agente anticanceroso
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
Garay et al. Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis
RU2010108429A (ru) Регуляторы ммр-9 и их применение
Park et al. Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina
MX2024010539A (es) Metodos para tratar enfermedades asociadas con ciliopatias.
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
MX2024003650A (es) Metodos de dosificacion de inhibidores de transportador apical de acidos biliares dependiente de sodio (asbtis).
Horvat et al. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
Cardoso et al. Physical exercise prevents memory impairment in an animal model of hypertension through modulation of CD39 and CD73 activities and A2A receptor expression
Nausieda et al. Bromocriptine-induced behavioral hypersensitivity: implications for the therapy of parkinsonism
Li et al. Effects of propofol on the activation of hippocampal CaMKIIα in depressed rats receiving electroconvulsive therapy
JP2024000505A5 (cg-RX-API-DMAC7.html)
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
MX2022006071A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa.
Park et al. Electroacupuncture to ST36 ameliorates behavioral and biochemical responses to restraint stress in rats
Higuchi et al. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report
Fujita Report of the american heart association (AHA) scientific sessions 2012, Los Angeles

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SAGE THERAPEUTICS, LLC (US)

B25G Requested change of headquarter approved

Owner name: SAGE THERAPEUTICS, LLC (US)

B25G Requested change of headquarter approved

Owner name: SAGE THERAPEUTICS, LLC (US)